Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19

 Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19

Amgen and Adaptive Biotechnologies Collaborate to Develop Therapies Targeting COVID-19

Shots:

  • The collaboration leverages Adaptive’s immune medicine platform for the identification of virus-neutralizing Abs with Amgen’s proficiency in immunology and novel Abs development
  • Adaptive extends immune medicine platform to discover Abs from recovered COVID-19 patients, which enables the company to identify Abs from survivors of COVID-19 to select those that neutralize SARS-CoV-2
  • Amgen will leverage its expertise to select, develop and manufacture Abs designed to bind and neutralize SARS-CoV-2. Additionally, both the companies have signed an MoU enabling the partners to commence the work immediately and are planning to execute a collaboration and license agreement

Click here ­to­ read full press release/ article | Ref: Amgen | Image: Biospace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post